Progenity, Inc.

40 articles with Progenity, Inc.

• Progenity Announces $40 Million Private Placement

  6/10/2021

  Progenity, Inc. today announced that it has entered into a definitive securities purchase agreement with two leading healthcare-focused investment funds for the sale of units consisting of shares of common stock.

• Progenity Launches Strategic Transformation into Biotech Company, Eliminating Costs of Progenity Genetics Lab and Focusing on Robust, Innovative R&D Pipeline

  6/2/2021

  Closure of genetics lab and other operational improvements expected to result in approximately 70% reduction of annual capital required for operations – from more than $180 million currently to targeted operating expenses of ~$50 million in 2022

• Progenity Provides Results from Key Study for Its Targeted Therapeutics Program

  5/26/2021

  Progenity , Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced results from a further study for the company’s Targeted Therapeutics program. The study evaluated delivery of Progenity’s PGN-001 (adalimumab) drug substance directly to the colon in a preclinical model of colitis.

• Sean Lavin, MD, Joins Progenity as Vice President, Business Development, Strategy, and Investor Relations

  5/25/2021

  Progenity, Inc., an innovative biotechnology company, announced the appointment of Sean Lavin, M.D. as Vice President, Business Development, Strategy, and Investor Relations.

• Progenity Joins Global Call to Raise Awareness of Preeclampsia in Pregnancy on World Preeclampsia Day – May 22ndProvides educational resources for both patients and healthcare providers

  5/21/2021

  Progenity, Inc . (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products in women’s health, joins the global call to raise awareness of preeclampsia in pregnancy on World Preeclampsia Day, on Saturday, May 22. 

• Progenity Provides Corporate Update and Reports First Quarter 2021 Financial Results

  5/13/2021

  Announced pre-validation data for its Preecludia™ test showed strong performance consistent with verification study and demonstrated commercial laboratory systems readiness

• Progenity Provides Preliminary Results from Key Studies for its Targeted Therapeutics Program

  5/12/2021

  Progenity , Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced preliminary results, subject to final audited study reports by its contract research organization (CRO), from two key studies for the Company’s Targeted Therapeutics program. The studies involved both the first functional clinical study of the Drug Delivery System (DDS), and the first preclinical study of PGN-600 (liquid tofacitinib delivered by DDS), one of the Co

• Progenity Receives Funding from Crohn’s & Colitis Foundation IBD Ventures Fund to Develop Drug Delivery System for IBD

  5/11/2021

  Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, announced today that it has received funding from the Crohn’s & Colitis Foundation’s IBD Ventures program to further develop Progenity’s first-in-class oral Drug Delivery System (DDS) for delivery of targeted therapeutics for inflammatory bowel disease (IBD).

• Progenity to Report First Quarter 2021 Financial Results and Provide Corporate Update

  5/6/2021

  Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report first quarter 2021 financial results on Thursday, May 13, 2021 after the close of financial markets. Progenity’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results

• Survey Reveals Pregnant Women Lack Awareness About Preeclampsia, the #2 Cause of Maternal Death

  5/4/2021

  Progenity survey showsmore women know their baby’s “fruit size” than the key indicator of a common pregnancy complication

• Progenity Presents Key Verification Study Data for Preecludia™ Preeclampsia Rule-out Test at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting

  4/30/2021

  Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced new data from its Preecludia preeclampsia rule-out test verification study are being presented today at the 2021 ACOG Annual Meeting

• Progenity to Present Two Abstracts for Novel Ingestible Drug Delivery Technologies at Digestive Disease Week 2021

  4/26/2021

  Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that two abstracts related to Progenity’s ingestible drug delivery technologies for the treatment of gastrointestinal disorders have been accepted for presentation at Digestive Disease Week ® (DDW). The DDW Virtual Meeting, taking place May 21-23, 2021, is the world’s prem

• Progenity to Present Key Prospective Verification Study Data for its Preeclampsia Rule-Out Test at 2021 American College of Obstetricians and Gynecologists Annual Meeting

  4/8/2021

  Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products in women’s health, will be presenting verification study data for its Preecludia™ rule-out test for preeclampsia at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting set to take place April 30 – May 2, 2021.

• Progenity and Ionis Pharmaceuticals Enter into Agreement to Evaluate Progenity’s Ingestible Oral Biotherapeutics Technology for Delivery of Antisense Therapies

  4/6/2021

  Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, today announced an agreement with Ionis Pharmaceuticals, the leader in RNA-targeted therapeutics, to evaluate the safety, tolerability and performance of Progenity’s Oral Biotherapeutics Delivery System (OBDS) for oral systemic delivery of antisense oligonucleotides

• Progenity Provides Corporate Updates and Reports Fourth Quarter and Full-Year 2020 Financial Results

  3/18/2021

  Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today provided corporate updates and reported financial results for the fourth quarter and full-year ended December 31, 2020.

• Progenity to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

  3/12/2021

  Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, March 18, 2021 after the close of financial markets.

• Progenity Announces $25 Million Private Placement

  2/23/2021

  Progenity, Inc. announced that it has entered into a definitive securities purchase agreement with two leading healthcare-focused investment funds for the sale of units consisting of shares of common stock and warrants to purchase common stock, as described below, in a private placement expected to result in gross proceeds to Progenity of approximately $25 million, before deducting placement agent commissions and other offering expenses.

• Progenity Initiates Safety and Tolerability Study of its Smart Capsule-Based Oral Drug Delivery System for GI Diseases

  2/17/2021

  Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, today announced the initiation of a clinical study for their Drug Delivery System (DDS) capsule, an ingestible and self-guided drug delivery device.

• SMFM Conference and Publications Highlight the Challenges and Complexities of Diagnosing and Managing Preeclampsia

  2/12/2021

  Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, applauds the continuing focus of the Society for Maternal-Fetal Medicine (SMFM) on the challenges of diagnosing and managing preeclampsia.

• Progenity to Participate in Two Upcoming Investor Conferences - Feb 10, 2021

  2/10/2021

  Progenity, Inc., a biotechnology company with an established track record of success in developing and commercializing molecular testing products, announced that Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of Progenity, is scheduled to participate in two upcoming virtual investor conferences: